No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)

byTeddy Guo

June 19, 2021

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy

RelatedReports

Dermatology

Microneedling with tranexamic acid may improve outcomes for patients with melasma

August 26, 2025

Pharma

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

July 8, 2025

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified

Chronic Disease

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

August 27, 2025

Pharma

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

June 4, 2025

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

Pirtobrutinib is safe and efficacious in the treatment of relapsed or refractory B-cell malignancies (BRUIN Trial)

Parents often unaware of adolescents’ suicidal thoughts

Ketamine infusion significantly reduces depressive symptoms among adolescents with treatment-resistant depression

$#VisualAbstract MRCN-003/CCTGMYX.1: Weekly carfilzomib, cyclophosphamide, and dexamethasone may be a safe and effective option for patients with relapsed/refractory multiple myeloma$

#VisualAbstract MRCN-003/CCTGMYX.1: Weekly carfilzomib, cyclophosphamide, and dexamethasone may be a safe and effective option for patients with relapsed/refractory multiple myeloma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports